MAPT and supranuclear palsy, progressive, 1: Despite the distinct involvement of α-synuclein and tau in parkinsonisms, their potential role as biomarkers in distinguishing between PD and PSP patients has been scarcely investigated [13,22,23,24,25,26,27,30].